Denali Capital (NASDAQ:DECA) announced in an 8-K that it has added $18 million in equity funding to its combination with biotech firm Longevity through the sale of newly issued series A preferred shares.
FutureTech Capital has agreed to purchase 1,800,000 such shares at $10 per share and Denali plans to issue at least 200,000 more preferred shares to investors not covered in this purchase. When announcing the business combination, Denali noted it aimed to raise a $30 million PIPE and it must provide $30 million in cash in order for the deal to close.
These preferred shares will be convertible into ordinary shares at the lower of $8 or the 20-day VWAP of the company stock multiplied by 80%. The parties have set a floor price for such conversion at $5 and all prices may be further adjusted for dividends, stock splits or other corporate actions. Otherwise, these preferred shares will have the same voting power and dividend rights as ordinary shares.
Denali Capital initially announced its $236.2 million combination with Longevity in January. Bothell, Washington-based Longevity is building a platform to consolidate a number of clinical-stage therapies, beginning with treatment candidates aiming to improve outcomes of certain vascular conditions as well as replace lost tissue.
ChampionsGate Acquisition Corporation (NASDAQ:CHPGU) has filed for a $200 million SPAC and is underwriter Clear Street’s fifth SPAC to file so far this year. This puts Clear Street above recent SPAC mainstays like EF Hutton, Maxim Group and Alliance Global partners and it appears to have carved out a portion of the market for itself,...
At the SPAC of Dawn Tuesday brings a big day of US retail sales readings, which generally get outsized attention in the thick of the holiday season. A pair of US retail sales indicators are set to report at 8:30 am ET, while industrial production figures and capacity utilization are set for a 9:15 am...
Jackson Acquisition Company II (NYSE:JACS.U) announced the pricing of its $200 million IPO and its units are expected to begin trading on the NYSE under the symbol “JACS.U”, Tuesday, December 10 2024. The new SPAC intends to search for a healthcare target that can benefit from its team’s relationships within the healthcare services space nationally....
SPAC deal flow has hit a slump in the second half of 2024 as the SPAC ecosystem transitions from one generation of SPACs to another. This year started with 128 SPACs still searching for a target and 102 SPACs are still in that state today. So, one might expect a more vigorous pace of announced...
At the SPAC of Dawn The second week of December kicks off with plenty of business on the schedule. Eight SPACs are holding votes of some kind while both Swiftmerge (NASDAQ:IVCP) and Mars (NASDAQ:MARX) ask their shareholders for approval of their deals. Swiftmerge has been working to take natural gas producer AleAnna public since June...